UniPharma Co., Ltd.
UniPharma Co., Ltd. engages in the distribution of pharmaceutical drugs, medical devices, and diagnostic tests in Taiwan. It provides diagnostic tests in areas of oncology, gynecology, orthopedics, neurology, anesthesiology, and cardiology. The company offers Adept reduction solution; bain, esmolol HCI, and naloxone anesthesia injections; Elisa DR-70 test for in-vitro diagnostics of tumors; and f… Read more
UniPharma Co., Ltd. (6621) - Total Liabilities
Latest total liabilities as of June 2025: NT$40.37 Million TWD
Based on the latest financial reports, UniPharma Co., Ltd. (6621) has total liabilities worth NT$40.37 Million TWD as of June 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
UniPharma Co., Ltd. - Total Liabilities Trend (2019–2024)
This chart illustrates how UniPharma Co., Ltd.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
UniPharma Co., Ltd. Competitors by Total Liabilities
The table below lists competitors of UniPharma Co., Ltd. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jaya Agra Wattie Tbk
JK:JAWA
|
Indonesia | Rp2.56 Trillion |
|
Pelangio Exploration Inc
PINK:PGXPF
|
USA | $543.51K |
|
Silvair Inc
WAR:SVRS
|
Poland | zł6.29 Million |
|
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
|
USA | $4.25 Million |
|
FuelPositive Corp
OTCQB:NHHHF
|
USA | $2.86 Million |
|
AMJ Global Technology
PINK:AMJT
|
USA | $1.19 Million |
|
Arcure SA
PA:ALCUR
|
France | €12.70 Million |
|
Mega Manunggal Property TBK PT
JK:MMLP
|
Indonesia | Rp1.83 Trillion |
Liability Composition Analysis (2019–2024)
This chart breaks down UniPharma Co., Ltd.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 6.19 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.16 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.14 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how UniPharma Co., Ltd.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for UniPharma Co., Ltd. (2019–2024)
The table below shows the annual total liabilities of UniPharma Co., Ltd. from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | NT$44.22 Million | +18.24% |
| 2023-12-31 | NT$37.40 Million | +27.51% |
| 2022-12-31 | NT$29.33 Million | -42.04% |
| 2021-12-31 | NT$50.61 Million | +38.31% |
| 2020-12-31 | NT$36.59 Million | -33.39% |
| 2019-12-31 | NT$54.94 Million | -- |